Cargando…

Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor

Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jian, Feng, Zhe-Xiang, Ren, Tao, Meng, Wei-Yu, Khan, Imran, Fan, Xing-Xing, Pan, Hu-Dan, Liu, Liang, Tang, Yi-Jun, Yao, Xiao-Jun, Li, Run-Ze, Wang, Mei-Fang, Leung, Elaine Lai-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575824/
https://www.ncbi.nlm.nih.gov/pubmed/36254028
http://dx.doi.org/10.1097/MD.0000000000031027
_version_ 1784811396513398784
author Wang, Jian
Feng, Zhe-Xiang
Ren, Tao
Meng, Wei-Yu
Khan, Imran
Fan, Xing-Xing
Pan, Hu-Dan
Liu, Liang
Tang, Yi-Jun
Yao, Xiao-Jun
Li, Run-Ze
Wang, Mei-Fang
Leung, Elaine Lai-Han
author_facet Wang, Jian
Feng, Zhe-Xiang
Ren, Tao
Meng, Wei-Yu
Khan, Imran
Fan, Xing-Xing
Pan, Hu-Dan
Liu, Liang
Tang, Yi-Jun
Yao, Xiao-Jun
Li, Run-Ze
Wang, Mei-Fang
Leung, Elaine Lai-Han
author_sort Wang, Jian
collection PubMed
description Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentiating TB from a malignant tumor. A total of 815 patients who were diagnosed with TB or cancer in Hubei Shiyan Taihe Hospital from 2014 to 2017 were collected. Amongst them, 717 were found to have PE by thoracoscopy. Clinical characteristics, patients’ blood parameters and PE indicator information were summarized for analysis. Patients with MPE had higher percentages to be bloody and negative of Rivalta test in PE than those with TPE. For clinical indicators, comparison of the specific parameters in blood showed that 18 indicators were higher in the TPE group than in the MPE group. By contrast, 12 indicators were higher in the MPE group than in the TPE group (P < .01). In addition, in PE tests, 3 parameters were higher in the TPE group, whereas other 4 parameters were higher in the MPE group (P < .01). Then, for clinical diagnosing practice, ROC analysis and principal component analysis were applied. The top 6 relevant indicators with area under curve over 0.70 were screened out as follows: hydrothorax adenosine dehydrogenase (pADA, 0.90), hydrothorax high-sensitivity C reactive protein (0.79), percentage of blood monocyte (sMONp, 0.75), blood high-sensitivity C reactive protein (sHsCRP, 0.73), erythrocyte sedimentation rate (0.71) and blood D-dimer (0.70). Moreover, logistic regression model revealed that a specific combination of 3 biomarkers, namely, pADA, sMONp and sHsCRP, could enhance the distinguishment of TB from malignant tumor with PE (area under curve = 0.944, 95% confidence interval = 0.925–0.964). The diagnostic function of the top single marker pADA in patients from different groups was analyzed and it was found to maintain high specificity and sensitivity. The 6 indicators, namely, pADA, hydrothorax high-sensitivity C reactive protein, sMONp, sHsCRP, sESR and blood D-dimer, showed significant diagnostic value for clinicians. Further, the combination of pADA, sMONp and sHsCRP has high accuracy for differential diagnosis for the first time. Most interestingly, the single marker pADA maintained high specificity and sensitivity in patients with different statuses and thus has great value for rapid and accurate diagnosis of suspected cases.
format Online
Article
Text
id pubmed-9575824
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-95758242022-10-17 Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor Wang, Jian Feng, Zhe-Xiang Ren, Tao Meng, Wei-Yu Khan, Imran Fan, Xing-Xing Pan, Hu-Dan Liu, Liang Tang, Yi-Jun Yao, Xiao-Jun Li, Run-Ze Wang, Mei-Fang Leung, Elaine Lai-Han Medicine (Baltimore) 5700 Oncology Pleural effusion (PE) is a common manifestation of tuberculosis (TB) and malignant tumors but tuberculous PE (TPE) is difficult to distinguish from malignant PE (MPE), especially by noninvasive detection indicators. This study aimed to find effective detection indices in blood and PE for differentiating TB from a malignant tumor. A total of 815 patients who were diagnosed with TB or cancer in Hubei Shiyan Taihe Hospital from 2014 to 2017 were collected. Amongst them, 717 were found to have PE by thoracoscopy. Clinical characteristics, patients’ blood parameters and PE indicator information were summarized for analysis. Patients with MPE had higher percentages to be bloody and negative of Rivalta test in PE than those with TPE. For clinical indicators, comparison of the specific parameters in blood showed that 18 indicators were higher in the TPE group than in the MPE group. By contrast, 12 indicators were higher in the MPE group than in the TPE group (P < .01). In addition, in PE tests, 3 parameters were higher in the TPE group, whereas other 4 parameters were higher in the MPE group (P < .01). Then, for clinical diagnosing practice, ROC analysis and principal component analysis were applied. The top 6 relevant indicators with area under curve over 0.70 were screened out as follows: hydrothorax adenosine dehydrogenase (pADA, 0.90), hydrothorax high-sensitivity C reactive protein (0.79), percentage of blood monocyte (sMONp, 0.75), blood high-sensitivity C reactive protein (sHsCRP, 0.73), erythrocyte sedimentation rate (0.71) and blood D-dimer (0.70). Moreover, logistic regression model revealed that a specific combination of 3 biomarkers, namely, pADA, sMONp and sHsCRP, could enhance the distinguishment of TB from malignant tumor with PE (area under curve = 0.944, 95% confidence interval = 0.925–0.964). The diagnostic function of the top single marker pADA in patients from different groups was analyzed and it was found to maintain high specificity and sensitivity. The 6 indicators, namely, pADA, hydrothorax high-sensitivity C reactive protein, sMONp, sHsCRP, sESR and blood D-dimer, showed significant diagnostic value for clinicians. Further, the combination of pADA, sMONp and sHsCRP has high accuracy for differential diagnosis for the first time. Most interestingly, the single marker pADA maintained high specificity and sensitivity in patients with different statuses and thus has great value for rapid and accurate diagnosis of suspected cases. Lippincott Williams & Wilkins 2022-10-14 /pmc/articles/PMC9575824/ /pubmed/36254028 http://dx.doi.org/10.1097/MD.0000000000031027 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5700 Oncology
Wang, Jian
Feng, Zhe-Xiang
Ren, Tao
Meng, Wei-Yu
Khan, Imran
Fan, Xing-Xing
Pan, Hu-Dan
Liu, Liang
Tang, Yi-Jun
Yao, Xiao-Jun
Li, Run-Ze
Wang, Mei-Fang
Leung, Elaine Lai-Han
Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title_full Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title_fullStr Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title_full_unstemmed Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title_short Novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
title_sort novel clinical biomarkers in blood and pleural effusion for diagnosing patients with tuberculosis distinguishing from malignant tumor
topic 5700 Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575824/
https://www.ncbi.nlm.nih.gov/pubmed/36254028
http://dx.doi.org/10.1097/MD.0000000000031027
work_keys_str_mv AT wangjian novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT fengzhexiang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT rentao novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT mengweiyu novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT khanimran novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT fanxingxing novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT panhudan novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT liuliang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT tangyijun novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT yaoxiaojun novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT lirunze novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT wangmeifang novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor
AT leungelainelaihan novelclinicalbiomarkersinbloodandpleuraleffusionfordiagnosingpatientswithtuberculosisdistinguishingfrommalignanttumor